Three-Year Outcomes of Wet Age-Related Macular Degeneration Treatment in Polish Therapeutic Programs
<i>Background and Objectives</i>: Wet age-related macular degeneration (wAMD) is a chronic, progressive disease of the central part of the retina. Standard treatment for wAMD consists of multiple intravitreal injections of anti-vascular endothelial growth factor drugs. The study goal was...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-12-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1648-9144/58/1/42 |
| _version_ | 1827664425493987328 |
|---|---|
| author | Małgorzata Figurska Marek Rękas |
| author_facet | Małgorzata Figurska Marek Rękas |
| author_sort | Małgorzata Figurska |
| collection | DOAJ |
| description | <i>Background and Objectives</i>: Wet age-related macular degeneration (wAMD) is a chronic, progressive disease of the central part of the retina. Standard treatment for wAMD consists of multiple intravitreal injections of anti-vascular endothelial growth factor drugs. The study goal was to evaluate the three-year effectiveness of wAMD treatment with aflibercept and ranibizumab as part of the therapeutic program in routine clinical practice. <i>Materials and Methods</i>: 1430 patients (possessing 1430 wAMD eyes) with median age of 78.0 years (71.0, 83.0) were enrolled in a non-randomized, retrospective, observational, multicenter study; 804 (56.2%) eyes were treatment-naïve. Therapy was carried out in accordance with the guidelines of the treatment program (the fixed or <i>pro re nata</i> regimen). <i>Results</i>: After the first year of treatment, there was a gain of 2.03 (12.15) letters; after the second, 0.94 (13.72) (<i>p</i> ˂ 0.001); and after the third, 0.17 (14.05) (<i>p</i> ˂ 0.001). There was a significant reduction in the central retinal thickness. In the first year, the patients received 7.00 (5.00, 8.00) injections. In the following years, a significantly lower number of injections (4.00 (2.00, 5.00)) was administered. After the first year, there was a significant difference in the distribution of the best corrected visual acuity according to the Early Treatment Diabetic Retinopathy Study protocol, with more frequent values in the ranges > 35 ≤ 70 for this parameter and > 70 letters in the treatment naïve eye subgroup. After the first year, central retinal thickness in treatment-naïve eyes was significantly reduced. <i>Conclusions</i>: Regular treatment of wet age-related macular degeneration as part of the treatment program achieves functional stabilization and significant morphological improvement over a long-term, three-year follow-up, with significantly fewer injections needed after the first year of treatment. |
| first_indexed | 2024-03-10T01:00:51Z |
| format | Article |
| id | doaj.art-a84d2a6bb28f4f009569030b1bcd77e0 |
| institution | Directory Open Access Journal |
| issn | 1010-660X 1648-9144 |
| language | English |
| last_indexed | 2024-03-10T01:00:51Z |
| publishDate | 2021-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj.art-a84d2a6bb28f4f009569030b1bcd77e02023-11-23T14:35:59ZengMDPI AGMedicina1010-660X1648-91442021-12-015814210.3390/medicina58010042Three-Year Outcomes of Wet Age-Related Macular Degeneration Treatment in Polish Therapeutic ProgramsMałgorzata Figurska0Marek Rękas1Department of Ophthalmology, Military Institute of Medicine, The Central Clinical Hospital of the Ministry of National Defense, 04-141 Warsaw, PolandDepartment of Ophthalmology, Military Institute of Medicine, The Central Clinical Hospital of the Ministry of National Defense, 04-141 Warsaw, Poland<i>Background and Objectives</i>: Wet age-related macular degeneration (wAMD) is a chronic, progressive disease of the central part of the retina. Standard treatment for wAMD consists of multiple intravitreal injections of anti-vascular endothelial growth factor drugs. The study goal was to evaluate the three-year effectiveness of wAMD treatment with aflibercept and ranibizumab as part of the therapeutic program in routine clinical practice. <i>Materials and Methods</i>: 1430 patients (possessing 1430 wAMD eyes) with median age of 78.0 years (71.0, 83.0) were enrolled in a non-randomized, retrospective, observational, multicenter study; 804 (56.2%) eyes were treatment-naïve. Therapy was carried out in accordance with the guidelines of the treatment program (the fixed or <i>pro re nata</i> regimen). <i>Results</i>: After the first year of treatment, there was a gain of 2.03 (12.15) letters; after the second, 0.94 (13.72) (<i>p</i> ˂ 0.001); and after the third, 0.17 (14.05) (<i>p</i> ˂ 0.001). There was a significant reduction in the central retinal thickness. In the first year, the patients received 7.00 (5.00, 8.00) injections. In the following years, a significantly lower number of injections (4.00 (2.00, 5.00)) was administered. After the first year, there was a significant difference in the distribution of the best corrected visual acuity according to the Early Treatment Diabetic Retinopathy Study protocol, with more frequent values in the ranges > 35 ≤ 70 for this parameter and > 70 letters in the treatment naïve eye subgroup. After the first year, central retinal thickness in treatment-naïve eyes was significantly reduced. <i>Conclusions</i>: Regular treatment of wet age-related macular degeneration as part of the treatment program achieves functional stabilization and significant morphological improvement over a long-term, three-year follow-up, with significantly fewer injections needed after the first year of treatment.https://www.mdpi.com/1648-9144/58/1/42wet age-related macular degenerationintravitreal injectionsafliberceptranibizumabelectronic registry |
| spellingShingle | Małgorzata Figurska Marek Rękas Three-Year Outcomes of Wet Age-Related Macular Degeneration Treatment in Polish Therapeutic Programs Medicina wet age-related macular degeneration intravitreal injections aflibercept ranibizumab electronic registry |
| title | Three-Year Outcomes of Wet Age-Related Macular Degeneration Treatment in Polish Therapeutic Programs |
| title_full | Three-Year Outcomes of Wet Age-Related Macular Degeneration Treatment in Polish Therapeutic Programs |
| title_fullStr | Three-Year Outcomes of Wet Age-Related Macular Degeneration Treatment in Polish Therapeutic Programs |
| title_full_unstemmed | Three-Year Outcomes of Wet Age-Related Macular Degeneration Treatment in Polish Therapeutic Programs |
| title_short | Three-Year Outcomes of Wet Age-Related Macular Degeneration Treatment in Polish Therapeutic Programs |
| title_sort | three year outcomes of wet age related macular degeneration treatment in polish therapeutic programs |
| topic | wet age-related macular degeneration intravitreal injections aflibercept ranibizumab electronic registry |
| url | https://www.mdpi.com/1648-9144/58/1/42 |
| work_keys_str_mv | AT małgorzatafigurska threeyearoutcomesofwetagerelatedmaculardegenerationtreatmentinpolishtherapeuticprograms AT marekrekas threeyearoutcomesofwetagerelatedmaculardegenerationtreatmentinpolishtherapeuticprograms |